Prdm16 Deficiency Leads to Age-Dependent Cardiac Hypertrophy, Adverse Remodeling, Mitochondrial Dysfunction, and...

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Aging Research

Background:

• Hypertrophic cardiomyopathy (HCM) is a significant cause of heart failure and mortality.
• While cardiac hypertrophy can be adaptive, prolonged growth leads to pathological remodeling and heart failure.
• The role of specific regulatory factors in maintaining adult cardiac function and preventing age-related decline is not fully understood.

Purpose of the Study:

• To investigate the role of Prdm16 in the adult heart.
• To determine if Prdm16 is required for maintaining cardiac function and preventing age-dependent hypertrophy.
• To elucidate the molecular mechanisms by which Prdm16 protects against pathological cardiac remodeling.

Main Methods:

• Generation of cardiac-specific Prdm16 knockout mouse models.
• Assessment of cardiac structure, function, and mitochondrial health in knockout and wild-type mice.
• Analysis of gene expression, including fetal gene reactivation and hypertrophic markers.
• Investigation of the interaction between Prdm16, Ehmts, and Myc in regulating cardiac gene expression.

Main Results:

• Prdm16 is dispensable for cardiac development but essential for adult heart function.
• Cardiac-specific deletion of Prdm16 causes age-dependent cardiac hypertrophy, fibrosis, mitochondrial dysfunction, and heart failure.
• Prdm16, with Ehmts, inhibits Myc activity to suppress fetal gene expression in pathological hypertrophy.
• Prdm16 knockout mice exhibit impaired metabolic flexibility and are susceptible to heart failure under metabolic stress.

Conclusions:

• Prdm16 is a critical regulator of mitochondrial function and metabolic flexibility in the adult heart.
• Prdm16 acts as a protective factor against age-dependent cardiac hypertrophy and heart failure.
• Targeting Prdm16 may offer a therapeutic strategy for preventing or treating age-related cardiovascular diseases.